go-203-2c
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01279603)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mucin-1INHIBITOR
MUC1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H]1CSSC[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(N)=O)C(=O)O)NC(=O)[C@@H](CCC(N)=O)NC1=O- Mol. weight
- 2352.82 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297466 ↗
Also known as
- go-203-2c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02658396 | Phase 1 | Jun 1, 2017 | Genus Oncology, LLC, Harvard University, National Institutes of Health (NIH) |
| NCT02204085 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Harvard University |
| NCT01279603 | Phase 1 | Jan 1, 2011 | Genus Oncology, LLC |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genus Oncology, LLC | For profit | 2 | 1 | 1 | 2011 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1